$316.24
0.38% yesterday
NYSE, Mar 21, 09:10 pm CET
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Amgen Target price 2025 - Analyst rating & recommendation

Amgen Classifications & Recommendation:

Buy
47%
Hold
44%
Sell
9%

Amgen Price Target

Target Price $314.96
Price $316.04
Deviation 0.34%
Number of Estimates 23
23 Analysts have issued a price target Amgen 2026 . The average Amgen target price is $314.96. This is 0.34% lower than the current stock price. The highest price target is $389.00 23.09% , the lowest is $185.00 41.46% .
A rating was issued by 32 analysts: 15 Analysts recommend Amgen to buy, 14 to hold and 3 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2026 of 0.34% . Most analysts recommend the Amgen stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029


Dec '24 2025
Estimates
Revenue Billion $ 33.23 35.20
18.64% 5.91%
EBITDA Margin 41.84% 51.03%
5.15% 21.96%
Net Margin 12.21% 16.82%
48.98% 37.71%

25 Analysts have issued a sales forecast Amgen 2025 . The average Amgen sales estimate is $35.2b . This is 5.91% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $35.9b 8.08% , the lowest is $34.6b 4.18% .

This results in the following potential growth metrics:

Revenue Estimates

2024 $33.2b 18.64%
2025 $35.2b 5.91%
2026 $36.0b 2.29%
2027 $36.6b 1.55%
2028 $36.8b 0.53%
2029 $38.0b 3.51%

10 Analysts have issued an Amgen EBITDA forecast 2025. The average Amgen EBITDA estimate is $18.0b . This is 25.44% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $21.4b 49.41% , the lowest is $14.3b 0.12% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $13.9b 12.54%
2025 $18.0b 29.17%
2026 $18.1b 0.83%
2027 $18.7b 3.31%
2028 $18.4b 1.89%
2029 $18.3b 0.50%

EBITDA Margin

2024 41.84% 5.15%
2025 51.03% 21.96%
2026 50.30% 1.43%
2027 51.18% 1.75%
2028 49.95% 2.40%
2029 48.01% 3.88%

9 Amgen Analysts have issued a net profit forecast 2025. The average Amgen net profit estimate is $5.9b . This is 46.04% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $7.8b 91.92% , the lowest is $4.0b 0.24% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $4.1b 39.47%
2025 $5.9b 45.84%
2026 $6.5b 10.39%
2027 $8.9b 36.53%
2028 $9.2b 3.03%
2029 $11.1b 20.54%

Net Margin

2024 12.21% 48.98%
2025 16.82% 37.71%
2026 18.15% 7.91%
2027 24.40% 34.44%
2028 25.01% 2.50%
2029 29.12% 16.43%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029


Dec '24 2025
Estimates
Earnings Per Share $ 7.56 11.03
39.47% 45.90%
P/E 28.66
EV/Sales 6.21

9 Analysts have issued a Amgen forecast for earnings per share. The average Amgen EPS is $11.03 . This is 46.09% higher than earnings per share in the financial year 2024. The highest EPS forecast is $14.49 91.92% , the lowest is $7.53 0.26% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $7.56 39.47%
2025 $11.03 45.90%
2026 $12.17 10.34%
2027 $16.62 36.57%
2028 $17.12 3.01%
2029 $20.64 20.56%

P/E ratio

Current 41.88 94.43%
2025 28.66 31.57%
2026 25.97 9.39%
2027 19.02 26.76%
2028 18.46 2.94%
2029 15.31 17.06%

Based on analysts' sales estimates for 2025, the Amgen stock is valued at an EV/Sales of 6.21 and an P/S ratio of 4.82 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.58 7.19%
2025 6.21 5.57%
2026 6.07 2.24%
2027 5.98 1.53%
2028 5.95 0.52%
2029 5.75 3.39%

P/S ratio

Current 5.11 0.69%
2025 4.82 5.58%
2026 4.72 2.24%
2027 4.64 1.52%
2028 4.62 0.53%
2029 4.46 3.39%

Current Amgen Upgrades & Downgrades

Analyst Rating Action Date
B of A Securities
Underperform
Underperform
Unchanged Mar 05 2025
Piper Sandler
Overweight
Overweight
Unchanged Feb 10 2025
B of A Securities
Underperform
Underperform
Unchanged Feb 06 2025
Citigroup
Neutral
Neutral
Unchanged Jan 28 2025
RBC Capital
Outperform
Outperform
Unchanged Jan 24 2025
Wells Fargo
Equal-Weight
Equal-Weight
Unchanged Jan 10 2025
Truist Securities
Hold
Hold
Unchanged Jan 08 2025
Analyst Rating Date
Unchanged
B of A Securities:
Underperform
Underperform
Mar 05 2025
Unchanged
Piper Sandler:
Overweight
Overweight
Feb 10 2025
Unchanged
B of A Securities:
Underperform
Underperform
Feb 06 2025
Unchanged
Citigroup:
Neutral
Neutral
Jan 28 2025
Unchanged
RBC Capital:
Outperform
Outperform
Jan 24 2025
Unchanged
Wells Fargo:
Equal-Weight
Equal-Weight
Jan 10 2025
Unchanged
Truist Securities:
Hold
Hold
Jan 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today